A clinician’s perspective on boron neutron capture therapy: promising advances, ongoing trials, and future outlook

References

• Accelerator-based BNCT projects. [date unknown]. [accessed 2024 Apr 20]. https://isnct.net/bnct-boron-neutron-capture-therapy/accelerator-based-bnct-projects-2021/.
   Google Scholar
• Aihara T, Morita N, Kamitani N, Kumada H, Ono K, Hiratsuka J, Harada T. 2014. BNCT for advanced or recurrent head and neck cancer. Appl Radiat Isot. 88:12–15. doi:10.1016/j.apradiso.2014.04.007
   PubMed Web of Science ®Google Scholar
• Ali F, S Hosmane N, Zhu Y. 2020. Boron chemistry for medical applications. Molecules. 25(4):828. doi:10.3390/molecules25040828
   PubMed Web of Science ®Google Scholar
• Asbury AK, Ojemann RG, Nielsen SL, Sweet WH. 1972. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol. 31(2):278–303. doi:10.1097/00005072-197204000-00005
   PubMedGoogle Scholar
• Ban HS, Nakamura H. 2018. Recent development of nanoparticle-based boron delivery systems for neutron capture therapy. In: Hosmane NS, editor. Handbook of boron science: with applications in organometallics, catalysis, materials and medicine. Singapore: World Scientific Publishing; p. 49–68.
   Google Scholar
• Barth RF, Mi P, Yang W. 2018. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 38(1):35. doi:10.1186/s40880-018-0299-7
   PubMed Web of Science ®Google Scholar
• Barth RF, Zhang Z, Liu T. 2018. A realistic appraisal of boron neutron capture therapy as a cancer treatment modality. Cancer Commun (Lond). 38(1):36. doi:10.1186/s40880-018-0280-5
   PubMed Web of Science ®Google Scholar
• Borel C, Jung AC, Burgy M. 2020. Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. Cancers (Basel). 12(9):2691. doi:10.3390/cancers12092691
   PubMed Web of Science ®Google Scholar
• Cartelli DE, Capoulat ME, Baldo M, Sandín JCS, Igarzabal M, Grosso MFD, Valda AA, Canepa N, Gun M, Minsky DM, et al. 2020. Status of low-energy accelerator-based BNCT worldwide and in Argentina. Appl Radiat Isot. 166:109315. doi:10.1016/j.apradiso.2020.109315
   PubMed Web of Science ®Google Scholar
• Chang-Claude J, Popanda O, Tan X-L, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, et al. 2005. Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res. 11(13):4802–4809. doi:10.1158/1078-0432.CCR-04-2657
   PubMed Web of Science ®Google Scholar
• Chédeville AL, Madureira PA. 2021. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers (Basel). 13(3):542. doi:10.3390/cancers13030542
   PubMed Web of Science ®Google Scholar
• Chen Y-W, Lee Y-Y, Lin C-F, Huang T-Y, Ke S-H, Mu P-F, Pan P-S, Chen J-K, Lan T-L, Hsu P-C, et al. 2022. Compassionate treatment of brainstem tumors with boron neutron capture therapy: a case series. Life (Basel). 12(4):566. doi:10.3390/life12040566
   Web of Science ®Google Scholar
• ChiCTR. 2023. A Single-center, Single-arm Clinical Trial of the Safety and Efficacy of Boron Neutron Capture Therapy (BNCT) for Advanced Refractory Malignant Tumors. https://www.chictr.org.cn/showproj.html?proj=181032.
   Google Scholar
• Chow LQM. 2020. Head and neck cancer. N Engl J Med. 382(1):60–72. doi:10.1056/NEJMra1715715
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. 2000. Phase 1 Clinical Trial of Boron Neutron Capture Therapy (BNCT) Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma. https://clinicaltrials.gov/show/NCT04293289.
   Google Scholar
• ClinicalTrials.gov. 2023. A multi-centered, radiation dose escalation, open, exploratory, phase 1/2a clinical trial on the safety, efficacy and pharmacokinetic characteristics of BNCT(boron neutron capture therapy) in patients with recurrent high-grade gliomas. https://clinicaltrials.gov/ct2/show/NCT05737212.
   Google Scholar
• Das BC, Nandwana NK, Das S, Nandwana V, Shareef MA, Das Y, Saito M, Weiss LM, Almaguel F, Hosmane NS, et al. 2022. Boron chemicals in drug discovery and development: synthesis and medicinal perspective. Molecules. 27(9):2615. doi:10.3390/molecules27092615
   PubMed Web of Science ®Google Scholar
• Dymova MA, Taskaev SY, Richter VA, Kuligina EV. 2020. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond). 40(9):406–421. doi:10.1002/cac2.12089
   PubMed Web of Science ®Google Scholar
• Farhood B, Samadian H, Ghorbani M, Zakariaee SS, Knaup C. 2018. Physical, dosimetric and clinical aspects and delivery systems in neutron capture therapy. Rep Pract Oncol Radiother. 23(5):462–473. doi:10.1016/j.rpor.2018.07.002
   PubMedGoogle Scholar
• Fithroni AB, Kobayashi K, Uji H, Ishimoto M, Akehi M, Ohtsuki T, Matsuura E. 2022. Novel self-forming nanosized DDS particles for BNCT: utilizing a hydrophobic boron cluster and its molecular glue effect. Cells. 11(20):3307. doi:10.3390/cells11203307
   PubMed Web of Science ®Google Scholar
• Fort M, Guet S, Husheng S, Calitchi E, Belkacemi Y. 2016. Role of radiation therapy in melanomas: Systematic review and best practice in 2016. Crit Rev Oncol Hematol. 99:362–375. doi:10.1016/j.critrevonc.2016.01.016
   PubMed Web of Science ®Google Scholar
• Fukuda H, Hiratsuka J, Kobayashi T, Sakurai Y, Yoshino K, Karashima H, Turu K, Araki K, Mishima Y, Ichihashi M, et al. 2003. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med. 26(3):97–103. doi:10.1007/BF03178777
   PubMedGoogle Scholar
• Fukumitsu N, Matsumoto Y. 2021. Development of an imaging technique for boron neutron capture therapy. Cells. 10(8):2135. doi:10.3390/cells10082135
   PubMed Web of Science ®Google Scholar
• Futamura G, Kawabata S, Siba H, Kuroiwa T, Suzuki M, Kondo N, Ono K, Sakurai Y, Tanaka M, Todo T, et al. 2014. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy. Radiat Oncol. 9(1):237. doi:10.1186/s13014-014-0237-z
   PubMedGoogle Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. 2014. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370(8):699–708. doi:10.1056/NEJMoa1308573
   PubMed Web of Science ®Google Scholar
• Gong L, Luo M, Sun R, Qiu L, Chen C, Luo Z. 2021. Significant association between XRCC1 expression and its rs25487 polymorphism and radiotherapy-related cancer prognosis. Front Oncol. 11:654784. doi:10.3389/fonc.2021.654784
   PubMed Web of Science ®Google Scholar
• Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. 2022. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 233(9):780–786. doi:10.1038/s41415-022-5166-x
   PubMed Web of Science ®Google Scholar
• Hiramatsu R, Kawabata S, Miyatake S, Kuroiwa T, Easson MW, Vicente MG. 2011. Application of a novel boronated porphyrin (H(2)OCP) as a dual sensitizer for both PDT and BNCT. Lasers Surg Med. 43(1):52–58. doi:10.1002/lsm.21026
   PubMed Web of Science ®Google Scholar
• Hiratsuka J, Kamitani N, Tanaka R, Tokiya R, Yoden E, Sakurai Y, Suzuki M. 2020. Long-term outcome of cutaneous melanoma patients treated with boron neutron capture therapy (BNCT). J Radiat Res. 61(6):945–951. doi:10.1093/jrr/rraa068
   PubMed Web of Science ®Google Scholar
• Hiratsuka J, Kamitani N, Tanaka R, Yoden E, Tokiya R, Suzuki M, Barth RF, Ono K. 2018. Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget’s disease with curative responses. Cancer Commun (Lond). 38(1):38. doi:10.1186/s40880-018-0297-9
   PubMedGoogle Scholar
• Hirose K, Konno A, Hiratsuka J, Yoshimoto S, Kato T, Ono K, Otsuki N, Hatazawa J, Tanaka H, Takayama K, et al. 2021. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ((10)B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 155:182–187. doi:10.1016/j.radonc.2020.11.001
   PubMed Web of Science ®Google Scholar
• Hirose K, Sato M, Kato T, Takayama K, Suzuki M, Yamaguchi H, Seto I, Kikuchi Y, Murakami M, Takai Y, et al. 2022. Profile analysis of adverse events after boron neutron capture therapy for head and neck cancer: a sub-analysis of the JHN002 study. J Radiat Res. 63(3):393–401. doi:10.1093/jrr/rrac012
   PubMed Web of Science ®Google Scholar
• Hosmane NS, Maguire JA, Zhu Y, Takagaki M. 2012. Major neutron capture therapy (NCT) drug prototypes. In: Hosmane NS, Maguire JA, Zhu Y, Takagaki M, editors. Boron and gadolinium neutron capture therapy for cancer treatment. Singapore: World Scientific Publishing; p. 41–98.
   Google Scholar
• Igaki H, Murakami N, Nakamura S, Yamazaki N, Kashihara T, Takahashi A, Namikawa K, Takemori M, Okamoto H, Iijima K, et al. 2022. Scalp angiosarcoma treated with linear accelerator-based boron neutron capture therapy: A report of two patients. Clin Transl Radiat Oncol. 33:128–133. doi:10.1016/j.ctro.2022.02.006
   PubMed Web of Science ®Google Scholar
• Im H, Lee J, Ryu KY, Yi JY. 2020. Integrin alphavbeta3-Akt signalling plays a role in radioresistance of melanoma. Exp Dermatol. 29(6):562–569. doi:10.1111/exd.14102
   PubMed Web of Science ®Google Scholar
• Imahori Y, Ueda S, Ohmori Y, Sakae K, Kusuki T, Kobayashi T, Takagaki M, Ono K, Ido T, Fujii R, et al. 1998. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I. Clin Cancer Res. 4(8):1825–1832.
   PubMed Web of Science ®Google Scholar
• Inoue M, Lee CM, Ono K, Suzuki M, Tokunaga T, Sawa Y, Okumura M. 2010. Clinical effectiveness of boron neutron capture therapy for a recurrent malignant peripheral nerve sheath tumor in the mediastinum. J Thorac Oncol. 5(12):2037–2038. doi:10.1097/JTO.0b013e3181f1cd86
   PubMed Web of Science ®Google Scholar
• Ishiwata K, Ido T, Mejia AA, Ichihashi M, Mishima Y. 1991. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy. Int J Rad Appl Instrum A. 42(4):325–328. doi:10.1016/0883-2889(91)90133-l
   PubMedGoogle Scholar
• JRCT. 2020. Pilot clinical study of boron neutron capture therapy on post-radiotherapy, recurrent breast cancer (BNCTonrBC). https://jrct.niph.go.jp/en-latest-detail/jRCTs051180219?utm_medium=email&utm_source=transaction.
   Google Scholar
• JRCT. 2022. Pilot study of boron neutron capture therapy for recurrent breast cancer after radiotherapy. https://jrct.niph.go.jp/en-latest-detail/jRCTs031220371.
   Google Scholar
• JRCT. 2024a. Phase I clinical BNCT Trial to evaluate the safty of iBNCT001 and SPM-011, Accelerator-Based novel High-Power Neutron Source in patient with newly diagnosed glioblastoma. https://jrct.niph.go.jp/latest-detail/jRCT2032230554.
   Google Scholar
• JRCT. 2024b. An open label dose escalation study to investigate the safety and tolerability of boron neutron capture therapy (BNCT) with SPM-011 and BNCT treatment system (BNCT30) in patients with recurrent malignant glioma (WHO grade III and grade IV). https://jrct.niph.go.jp/latest-detail/jRCT2051210053.
   Google Scholar
• JRCT. 2024c. A phase II study of boron neutron capture therapy (BNCT) for patients with unresectable angiosarcoma, by using CICS-1 and SPM-011. https://jrct.niph.go.jp/latest-detail/jRCT2031220410.
   Google Scholar
• JRCT. 2024d. Phase 2 clinical trial of boron neutron capture therapy for recurrent high-grade meningioma using SPM-011 and BNCT30 - BNCT for high-grade meningioma. https://jrct.niph.go.jp/latest-detail/jRCT2051190044.
   Google Scholar
• Kageji T, Sogabe S, Mizobichi Y, Nakajima K, Shinji N, Nakagawa Y. 2015. Radiation-induced meningiomas after BNCT in patients with malignant glioma. Appl Radiat Isot. 106:256–259. doi:10.1016/j.apradiso.2015.06.004
   PubMed Web of Science ®Google Scholar
• Kankaanranta L, Saarilahti K, Mäkitie A, Välimäki P, Tenhunen M, Joensuu H. 2011. Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol. 99(1):98–99. doi:10.1016/j.radonc.2011.02.008
   PubMed Web of Science ®Google Scholar
• Kankaanranta L, Seppälä T, Koivunoro H, Saarilahti K, Atula T, Collan J, Salli E, Kortesniemi M, Uusi-Simola J, Välimäki P, et al. 2012. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 82(1):e67-75–e75. doi:10.1016/j.ijrobp.2010.09.057
   PubMedGoogle Scholar
• Kanno H, Nagata H, Ishiguro A, Tsuzuranuki S, Nakano S, Nonaka T, Kiyohara K, Kimura T, Sugawara A, Okazaki Y, et al. 2021. Designation products: boron neutron capture therapy for head and neck carcinoma. Oncologist. 26(7):e1250–e1255. doi:10.1002/onco.13805
   PubMed Web of Science ®Google Scholar
• Kao HF, Lou PJ. 2019. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: current landscape and future directions. Head Neck. 41 Suppl 1(S1):4–18. doi:10.1002/hed.25930
   PubMedGoogle Scholar
• Kato I, Fujita Y, Maruhashi A, Kumada H, Ohmae M, Kirihata M, Imahori Y, Suzuki M, Sakrai Y, Sumi T, et al. 2009. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies. Appl Radiat Isot. 67(7-8 Suppl):S37–S42. doi:10.1016/j.apradiso.2009.03.103
   PubMed Web of Science ®Google Scholar
• Khalil A, Adam MSS. 2024. Nucleoside scaffolds and carborane clusters for boron neutron capture therapy: developments and future perspective. Curr Med Chem. Epub ahead of print. doi:10.2174/0109298673245020230929152030
   Google Scholar
• Kimura Y, Ariyoshi Y, Miyatake S, Shimahara M, Kawabata S, Ono K. 2009. Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report. Int J Oral Maxillofac Surg. 38(3):293–295. doi:10.1016/j.ijom.2008.12.010
   PubMed Web of Science ®Google Scholar
• Kondo N, Hirano F, Temma T. 2022. Evaluation of 3-Borono-l-phenylalanine as a water-soluble boron neutron capture therapy agent. Pharmaceutics. 14(5):1106. doi:10.3390/pharmaceutics14051106
   PubMed Web of Science ®Google Scholar
• Kurosaki H, Okazaki K, Takemori M, Tate E, Nakamura T. 2024. The effects of boron neutron capture therapy on the lungs in recurrent breast cancer treatment. Cureus. 16(4):e57417. doi:10.7759/cureus.57417
   PubMed Web of Science ®Google Scholar
• Lamba M, Goswami A, Bandyopadhyay A. 2021. A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT). Chem Commun (Camb). 57(7):827–839. doi:10.1039/d0cc06557a
   PubMed Web of Science ®Google Scholar
• Lee W, Kim KW, Lim JE, Sarkar S, Kim JY, Chang Y, Yoo J. 2022. In vivo evaluation of the effects of combined boron and gadolinium neutron capture therapy in mouse models. Sci Rep. 12(1):13360. doi:10.1038/s41598-022-17610-4
   PubMed Web of Science ®Google Scholar
• Leśnikowski ZJ. 2016. New opportunities in boron chemistry for medical applications. In: Hosmane NS, editor. Boron science: new technologies and applications. Boca Raton (FL): CRC Press; p. 3–19.
   Google Scholar
• Li J, Shi Y, Zhang Z, Liu H, Lang L, Liu T, Chen X, Liu Z. 2019. A metabolically stable boron-derived tyrosine serves as a theranostic agent for positron emission tomography guided boron neutron capture therapy. Bioconjug Chem. 30(11):2870–2878. doi:10.1021/acs.bioconjchem.9b00578
   PubMed Web of Science ®Google Scholar
• Li J, Sun Q, Lu C, Xiao H, Guo Z, Duan D, Zhang Z, Liu T, Liu Z. 2022. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 13(1):2143. doi:10.1038/s41467-022-29780-w
   PubMed Web of Science ®Google Scholar
• Locher GL. 1936. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther. 36(1):1–18.
   Google Scholar
• Luderer MJ, de la Puente P, Azab AK. 2015. Advancements in tumor targeting strategies for boron neutron capture therapy. Pharm Res. 32(9):2824–2836. doi:10.1007/s11095-015-1718-y
   PubMed Web of Science ®Google Scholar
• Menéndez PR, Roth BMC, Pereira MD, Casal MR, González SJ, Feld DB, Santa Cruz GA, Kessler J, Longhino J, Blaumann H, et al. 2009. BNCT for skin melanoma in extremities: updated Argentine clinical results. Appl Radiat Isot. 67(7-8 Suppl):S50–S3. doi:10.1016/j.apradiso.2009.03.020
   PubMed Web of Science ®Google Scholar
• Mishima Y, Ichihashi M, Tsuji M, Hatta S, Ueda M, Honda C, Suzuki T. 1989. Treatment of malignant melanoma by selective thermal neutron capture therapy using melanoma-seeking compound. J Invest Dermatol. 92(5 Suppl):321S–325S. doi:10.1111/1523-1747.ep13076750
   PubMedGoogle Scholar
• Mishima Y, Imahori Y, Honda C, Hiratsuka J, Ueda S, Ido T. 1997. In vivo diagnosis of human malignant melanoma with positron emission tomography using specific melanoma-seeking 18F-DOPA analogue. J Neurooncol. 33(1-2):163–169. doi:10.1023/a:1005746020350
   PubMed Web of Science ®Google Scholar
• Miyatake S, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono K. 2007. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery. 61(1):82–91. doi:10.1227/01.neu.0000279727.90650.24
   PubMed Web of Science ®Google Scholar
• Miyatake S-I, Kawabata S, Goto H, Narita Y, Suzuki M, Hirose K, Takai Y, Ono K, Ohnishi T, Tanaka H, et al. 2020. Accelerator-based BNCT in rescue treatment of patients with recurrent GBM: A multicenter phase II study. JCO. 38(15_suppl):2536–2536. doi:10.1200/JCO.2020.38.15_suppl.2536
   Google Scholar
• Moss RL. 1993. Review of Reactor-Based Neutron Beam Development for BNCT Applications. In: Soloway AH, Barth RF, Carpenter DE, editors. Advances in neutron capture therapy. Boston (MA): Springer; p. 1–7. doi:10.1007/978-1-4615-2978-1_1
   Google Scholar
• Nakagawa Y, Hatanaka H. 1997. Boron neutron capture therapy. Clinical brain tumor studies. J Neurooncol. 33(1-2):105–115. doi:10.1023/a:1005781517624
   PubMed Web of Science ®Google Scholar
• Nakahara Y, Ito H, Masuoka J, Abe T. 2020. Boron neutron capture therapy and photodynamic therapy for high-grade meningiomas. Cancers (Basel). 12(5):1334. doi:10.3390/cancers12051334
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kirihata M. 2012. Boron compounds: new candidates for boron carriers in BNCT. In: Sauerwein W, Wittig A, Moss R, Nakagawa Y, editors. Neutron capture therapy. Berlin: Springer; p. 99–116. doi:10.1007/978-3-642-31334-9_7
   Google Scholar
• Nakase I, Aoki A, Sakai Y, Hirase S, Ishimura M, Takatani-Nakase T, Hattori Y, Kirihata M. 2020. Antibody-based receptor targeting using an fc-binding peptide-dodecaborate conjugate and macropinocytosis induction for boron neutron capture therapy. ACS Omega. 5(36):22731–22738. doi:10.1021/acsomega.0c01377
   PubMed Web of Science ®Google Scholar
• Nariai T, Ishiwata K. 2012. Analysis and Imaging: PET. In: Sauerwein W, Wittig A, Moss R, Nakagawa Y, editors. Neutron capture therapy. Berlin: Springer; p. 229–240. doi:10.1007/978-3-642-31334-9_11
   Google Scholar
• Ono K, Tanaka H, Tamari Y, Watanabe T, Suzuki M, Masunaga S-i 2019. Proposal for determining absolute biological effectiveness of boron neutron capture therapy—the effect of 10B (n, α) 7Li dose can be predicted from the nucleocytoplasmic ratio or the cell size. J Radiat Res. 60(1):29–36. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373679/pdf/rry080.pdf. doi:10.1093/jrr/rry080
   PubMed Web of Science ®Google Scholar
• Porra L, Wendland L, Seppälä T, Koivunoro H, Revitzer H, Tervonen J, Kankaanranta L, Anttonen A, Tenhunen M, Joensuu H, et al. 2023. From nuclear reactor-based to proton accelerator-based therapy: the finnish boron neutron capture therapy experience. Cancer Biother Radiopharm. 38(3):184–191. doi:10.1089/cbr.2022.0059
   PubMed Web of Science ®Google Scholar
• Sacco AG, Cohen EE. 2015. Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol. 33(29):3305–3313. doi:10.1200/JCO.2015.62.0963
   PubMed Web of Science ®Google Scholar
• Sauerwein WAG, Bet PM, Wittig A. 2012. Drugs for BNCT: BSH and BPA. In: Sauerwein WAG, Wittig A, Moss R, Nakagawa Y, editors. Neutron capture therapy: principles and applications. Berlin: Springer; p. 117–160. doi:10.1007/978-3-642-31334-9_8
   Google Scholar
• Shanmugam M, Kuthala N, Kong X, Chiang CS, Hwang KC. 2023. Combined gadolinium and boron neutron capture therapies for eradication of head-and-neck tumor using Gd(10)B(6) nanoparticles under MRI/CT image guidance. JACS Au. 3(8):2192–2205. doi:10.1021/jacsau.3c00250
   PubMedGoogle Scholar
• Sibrian-Vazquez M, Vicente MGH. 2011. Boron tumor-delivery for BNCT: recent developments and perspectives. In: Hosmane NS, editor. Boron science: new technologies and applications. Boca Raton (FL): CRC Press; p. 203–232.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. 2020. Cancer statistics, 2020. CA Cancer J Clin. 70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Slatkin DN. 1991. A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit. Brain. 114 (Pt 4):1609–1629. doi:10.1093/brain/114.4.1609
   PubMed Web of Science ®Google Scholar
• Stenstam BH, Pellettieri L, Sorteberg W, Rezaei A, Sköld K. 2007. BNCT for recurrent intracranial meningeal tumours - case reports. Acta Neurol Scand. 115(4):243–247. doi:10.1111/j.1600-0404.2006.00776.x
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352(10):987–996. doi:10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Suzuki M, Endo K, Satoh H, Sakurai Y, Kumada H, Kimura H, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, et al. 2008. A novel concept of treatment of diffuse or multiple pleural tumors by boron neutron capture therapy (BNCT). Radiother Oncol. 88(2):192–195. doi:10.1016/j.radonc.2008.06.009
   PubMed Web of Science ®Google Scholar
• Suzuki M, Kato I, Aihara T, Hiratsuka J, Yoshimura K, Niimi M, Kimura Y, Ariyoshi Y, Haginomori S-I, Sakurai Y, et al. 2014. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer. J Radiat Res. 55(1):146–153. doi:10.1093/jrr/rrt098
   PubMed Web of Science ®Google Scholar
• Suzuki M, Sakurai Y, Hagiwara S, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, Kudo M, Ono K. 2007. First attempt of boron neutron capture therapy (BNCT) for hepatocellular carcinoma. Jpn J Clin Oncol. 37(5):376–381. doi:10.1093/jjco/hym039
   PubMed Web of Science ®Google Scholar
• Sweet WH. 1997. Early history of development of boron neutron capture therapy of tumors. J Neurooncol. 33(1-2):19–26. doi:10.1023/a:1005752827194
   PubMed Web of Science ®Google Scholar
• Tabbakh F, Hosmane NS. 2020. Enhancement of radiation effectiveness in proton therapy: comparison between fusion and fission methods and further approaches. Sci Rep. 10(1):5466. doi:10.1038/s41598-020-62268-5
   PubMed Web of Science ®Google Scholar
• Takagaki M, Kazuko U, Hosmane NS. 2018. An overview of clinical and biological aspects of current boron neutron capture therapy (BNCT) for cancer treatment. In: Hosmane NS, Eagling R, editors. Handbook of boron science: with applications in organometallics, catalysis, materials and medicine, Volume 4: Boron in medicine. Singapore: World Scientific; p. 101–143. doi:10.1142/9781786344670_0005
   Google Scholar
• Takai S, Wanibuchi M, Kawabata S, Takeuchi K, Sakurai Y, Suzuki M, Ono K, Miyatake S-I. 2022. Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up. Neuro Oncol. 24(1):90–98. doi:10.1093/neuonc/noab108
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Kawabata S, Hiramatsu R, Matsushita Y, Tanaka H, Sakurai Y, Suzuki M, Ono K, Miyatake S-I, Kuroiwa T, et al. 2018. Boron neutron capture therapy for high-grade skull-base meningioma. J Neurol Surg B Skull Base. 79(Suppl 4):S322–S327. doi:10.1055/s-0038-1666837
   PubMedGoogle Scholar
• Tamura Y, Miyatake S-I, Nonoguchi N, Miyata S, Yokoyama K, Doi A, Kuroiwa T, Asada M, Tanabe H, Ono K, et al. 2006. Boron neutron capture therapy for recurrent malignant meningioma. Case report. J Neurosurg. 105(6):898–903. doi:10.3171/jns.2006.105.6.898
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. 2020. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 70(4):299–312. doi:10.3322/caac.21613
   PubMed Web of Science ®Google Scholar
• Ueda H, Suzuki M, Kuroda R, Tanaka T, Aoki S. 2021. Design, synthesis, and biological evaluation of boron-containing macrocyclic polyamines and Their Zinc(II) complexes for boron neutron capture therapy. J Med Chem. 64(12):8523–8544. doi:10.1021/acs.jmedchem.1c00445
   PubMed Web of Science ®Google Scholar
• UMIN. 2021. Boron neutron capture therapy using cyclotron-based epithermal neutron source for squamous cell carcinoma of the head and neck refractory to standard treatments: An open-label phase II trial - REBIVAL study. [accessed 2024 Apr 25]. https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050375.
   Google Scholar
• Vigneswaran N, Williams MD. 2014. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am. 26(2):123–141. doi:10.1016/j.coms.2014.01.001
   PubMed Web of Science ®Google Scholar
• Wang LW, Liu YH, Chou FI, Jiang SH. 2018. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun (Lond). 38(1):37. doi:10.1186/s40880-018-0295-y
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Z, Miao L, Li Y. 2022. Boron neutron capture therapy: current status and challenges. Front Oncol. 12:788770. doi:10.3389/fonc.2022.788770
   PubMed Web of Science ®Google Scholar
• Wu G, Barth RF, Yang W, Lee RJ, Tjarks W, Backer MV, Backer JM. 2006. Boron containing macromolecules and nanovehicles as delivery agents for neutron capture therapy. Anticancer Agents Med Chem. 6(2):167–184. doi:10.2174/187152006776119153
   PubMedGoogle Scholar
• Xu H, Liu J, Li R, Lin J, Gui L, Wang Y, Jin Z, Xia W, Liu Y, Cheng S, et al. 2024. Novel promising boron agents for boron neutron capture therapy: Current status and outlook on the future. Coord Chem Rev. 511:215795. doi:10.1016/j.ccr.2024.215795
   Web of Science ®Google Scholar
• Xuan S, Vicente MGH. 2018. Recent advances in boron delivery agents for Boron Neutron Capture Therapy (BNCT). In: Hey-Hawkins E, Teixidor F, editors. Boron-based compounds: potential and emerging applications in medicine. Chichester (UK): John Wiley & Sons; p. 298–326.
   Google Scholar
• Yamana K, Kawasaki R, Kondo K, Hirano H, Kawamura S, Sanada Y, Bando K, Tabata A, Azuma H, Takata T, et al. 2023. HER-2-targeted boron neutron capture therapy using an antibody-conjugated boron nitride nanotube/beta-1,3-glucan complex. Nanoscale Adv. 5(15):3857–3861. doi:10.1039/d3na00028a
   PubMed Web of Science ®Google Scholar
• Yanagie H, Higashi S, Seguchi K, Ikushima I, Fujihara M, Nonaka Y, Oyama K, Maruyama S, Hatae R, Suzuki M, et al. 2014. Pilot clinical study of boron neutron capture therapy for recurrent hepatic cancer involving the intra-arterial injection of a (10)BSH-containing WOW emulsion. Appl Radiat Isot. 88:32–37. doi:10.1016/j.apradiso.2014.01.014
   PubMed Web of Science ®Google Scholar
• Yong Z, Song Z, Zhou Y, Liu T, Zhang Z, Zhao Y, Chen Y, Jin C, Chen X, Lu J, et al. 2016. Boron neutron capture therapy for malignant melanoma: first clinical case report in China. Chin J Cancer Res. 28(6):634–640. doi:10.21147/j.issn.1000-9604.2016.06.10
   PubMed Web of Science ®Google Scholar
• Zhang X, Lin Y, Hosmane NS, Zhu Y. 2023. Nanostructured boron agents for boron neutron capture therapy: a review of recent patents. Med Rev (2021). 3(5):425–443. doi:10.1515/mr-2023-0013
   PubMedGoogle Scholar
• Zonta A, Pinelli T, Prati U, Roveda L, Ferrari C, Clerici AM, Zonta C, Mazzini G, Dionigi P, Altieri S, et al. 2009. Extra-corporeal liver BNCT for the treatment of diffuse metastases: what was learned and what is still to be learned. Appl Radiat Isot. 67(7-8 Suppl):S67–S75. doi:10.1016/j.apradiso.2009.03.087
   PubMed Web of Science ®Google Scholar